3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
4
Neuroma, Acoustic
1
Neurofibromatosis 2
1
NSCLC
1
Meningioma
1
Lymphoma, Large-Cell, Anaplastic
1
Granuloma, Plasma Cell
1
Ependymoma
1
ALK-positive Advanced NSCLC
1
ALK+ Advanced NSCLC
1
Interventions
Magnetic Resonance Spectroscopy
9
Cyclophosphamide
7
X-Rays
6
Temozolomide
6
Specimen Handling
6
Phantoms, Imaging
6
Biopsy
6
Nuclear Medicine Department, Hospital
5
Etoposide
5
Nivolumab
4
Bevacizumab
4
Radiation
3
Irinotecan
3
Automobiles
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
lutetium Lu 177 dotatate
2
larotrectinib
2
ivosidenib
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
abemaciclib
2
Watchful Waiting
2
Radiotherapy
2
ONC206
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
brigatinib
×
1 year
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled